复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

交易中 07-17 10:16:28

62.300

+2.650

+4.44%

最高62.650	最低59.650	成交量70.92万
今开59.650	昨收59.650	日振幅5.03%
总市值338.60亿	流通市值101.55亿	总股本5.43亿
成交额4,392万	换手率0.44%	流通股本1.63亿
市净率10.28	ROE31.52%	每股收益1.65
52周最高62.650	52周最低15.200	市盈率37.75
股息0.00	股息收益率0.00	ROA5.28%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":62.3,"timestamp":1752718573468,"preClose":59.65,"halted":0,"volume":709200,"delay":0,"floatShares":163000000,"shares":543494853,"eps":1.6505188400973385,"marketStatus":"交易中","change":2.65,"latestTime":"07-17 10:16:26","open":59.65,"high":62.65,"low":59.65,"amount":43920519,"amplitude":0.050293,"askPrice":62.3,"askSize":3300,"bidPrice":62.1,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.6505188400973385,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1752724800000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":59.65,"openAndCloseTimeList":[[1752715800000,1752724800000],[1752728400000,1752739200000]],"volumeRatio":3.575466,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2552912253","title":"每日卖空追踪 | 复宏汉霖 07月16日卖空量成交2.73万股，卖空比例为1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552912253","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552912253?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:30","pubTimestamp":1752654636,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间07月16日，涨8.36%，卖空量成交2.73万股%，较上一交易日增加76.13%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172717a6ad21bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172717a6ad21bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2552122537","title":"复宏汉霖07月16日获主力加仓1381.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552122537","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552122537?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:15","pubTimestamp":1752653721,"startTime":"0","endTime":"0","summary":"07月16日, 复宏汉霖股价涨8.36%，报收59.65元，成交金额1.3亿元，换手率1.34%，振幅11.08%，量比1.93。复宏汉霖今日主力资金净流入1381.1万元，连续3日净流入，上一交易日主力净流入3.9万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为28.57%，平均涨幅为6.41%。该股近5个交易日上涨5.99%，主力资金累计净流入2108.5万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入8304.4万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716165906a6ad0e38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716165906a6ad0e38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2551110768","title":"头部药企接连失利！该药物靶点在挫折中等待拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2551110768","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551110768?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:06","pubTimestamp":1752649616,"startTime":"0","endTime":"0","summary":"然而，近年来，围绕这一靶点的研发之路却布满荆棘，众多药企接连折戟，让 CD47 靶点的前景蒙上了一层厚重的阴霾。吉利德旗下的 magrolimab 多项临床试验因安全性问题屡屡受挫。这些接连不断的失利，让市场对 CD47 靶点的前景从最初的满怀憧憬转变为如今的疑虑重重。导致 CD47 靶点研发失败的原因错综复杂，其中毒性与疗效的平衡难题尤为突出。CD47 靶点从备受追捧到如今的接连折戟，无疑为整个生物医药行业敲响了警钟。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071615102197a81b50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071615102197a81b50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3B42.SGD","LU0985481810.HKD","SG9999001176.USD","LU0170899867.USD","LU1066053197.SGD","PFE","SGXZ57979304.SGD","LU0321505868.SGD","SG9999001176.SGD","LU0122379950.USD","09926","IE00BLSP4452.SGD","BK4550","IE0002270589.USD","LU0456855351.SGD","LU0289739699.SGD","BK4599","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU0321505439.SGD","LU0225771236.USD","SG9999003800.SGD","LU1066051498.USD","LU1057294990.SGD","SG9999002232.USD","BK4585","LU1894683348.USD","BK4588","IE00B19Z3581.USD","SG9999011175.SGD","BK4534","BK4007","LU0306807586.USD","BK4533","LU0225284248.USD","LU0868494617.USD","SG9999013999.USD","LU0306806265.USD","BK4592","LU0058720904.USD","LU1883839398.USD","BK4568","02696","BK4581","IE00BBT3K403.USD","LU1023059063.AUD","LU1894683264.USD","LU0234572021.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2551124121","title":"创新药概念走势向好 复宏汉霖涨9.72% 机构指板块估值仍具吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2551124121","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551124121?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:41","pubTimestamp":1752644466,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念走势向好，派格生物医药 涨10.83%，复宏汉霖涨9.72%，康方生物涨7.13%，亚盛医药涨4.25%，诺诚健华涨3.5%。对于创新药出海演变方向，该机构观察以下趋势：1）行业进一步衍生出了NewCo等新型交易模式；2）ADC赛道交易兴趣度最高，双抗/多抗、小核酸/mRNA等前沿技术领域亦存在较多机会。基于当前国产创新药资产储备丰富且交易性价比仍显着、MNC存在专利补缺需求、海外投融资边际改善，该机构认为2H25-2026年出海交易热度仍将延续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716135524a6acadc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716135524a6acadc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","02565","BK1161","09926","BK1574","09969","06855","02696"],"gpt_icon":0},{"id":"1139906462","title":"复宏汉霖飙涨逾10%！HLX22第三期临床研究已完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1139906462","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139906462?lang=zh_cn&edition=full","pubTime":"2025-07-16 09:54","pubTimestamp":1752630848,"startTime":"0","endTime":"0","summary":"7月16日，$复宏汉霖(02696)$飙涨逾10%，年内累涨逾155%！HLX22第三期临床研究已完成美国首例患者给药。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"复宏汉霖飙涨逾10%！HLX22第三期临床研究已完成美国首例患者给药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2551116155","title":"挑战全球一线治疗，复星医药子公司复宏汉霖HLX22头对头III期临床美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551116155","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551116155?lang=zh_cn&edition=full","pubTime":"2025-07-15 17:52","pubTimestamp":1752573120,"startTime":"0","endTime":"0","summary":"复宏汉霖启动HLX22对比一线疗法治疗HER2阳性晚期胃癌的III期临床研究，全球多中心进行，已完成美国首例患者给药，该疗法有望填补胃癌治疗空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071609511697a7cbe5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071609511697a7cbe5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1515","600196","BK1191","BK1161","02196","BK1593"],"gpt_icon":0},{"id":"2551304741","title":"复宏汉霖盘中异动 急速拉升5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551304741","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551304741?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:53","pubTimestamp":1752548039,"startTime":"0","endTime":"0","summary":"2025年07月15日早盘10时53分，复宏汉霖股票出现波动，股价大幅上涨5.18%。截至发稿，该股报54.850港元/股，成交量29.15万股，换手率0.18%，振幅5.08%。机构评级方面，在所有4家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。复宏汉霖股票所在的生物技术行业中，整体涨幅为1.44%。复宏汉霖公司简介：上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151053599542e16a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151053599542e16a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2551306931","title":"港股异动 | 复宏汉霖(02696)现涨超4% HLX22第三期临床研究已完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551306931","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551306931?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:45","pubTimestamp":1752547539,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖现涨超4%，截至发稿，涨4.22%，报54.35港元，成交额1458.2万港元。消息面上，复宏汉霖公布，近日，一项HLX22联合曲妥珠单抗和化疗对比曲妥珠单抗和化疗联合或不联合帕博利珠单抗一线治疗人类表皮生长因子受体2阳性局部晚期或转移性胃食管交界部和胃癌的国际多中心3期临床研究已完成美国首例患者给药。HLX22用于治疗胃癌已分别于2025年3月及2025年5月获美国食品药品监督管理局及欧盟委员会授予孤儿药资格认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 复宏汉霖(02696)现涨超4% HLX22第三期临床研究已完成美国首例患者给药","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2551901335","title":"复宏汉霖(02696)：HLX22联合疗法III期试验在美完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551901335","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551901335?lang=zh_cn&edition=full","pubTime":"2025-07-14 17:08","pubTimestamp":1752484126,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，一项HLX22(重组人源化抗 HER2单克隆抗体注射液)(“HLX22”)联合曲妥珠单抗和化疗(XELOX)对比曲妥珠单抗和化疗(XELOX)联合或不联合帕博利珠单抗一线治疗人类表皮生长因子受体2(HER2)阳性局部晚期或转移性胃食管交界部和胃癌的国际多中心3期临床研究已完成美国首例患者给药。该3期临床研究亦正于中国境内(不包括中国港澳台地区，下同)、澳大利亚及日本等国家/地区同步开展中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","III","BK4134"],"gpt_icon":0},{"id":"2551900727","title":"每日卖空追踪 | 复宏汉霖 07月14日卖空量成交1.26万股，卖空比例为1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551900727","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551900727?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:30","pubTimestamp":1752481830,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间07月14日，跌0.29%，卖空量成交1.26万股%，较上一交易日减少45.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172646a4498fc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172646a4498fc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2550939736","title":"每日卖空追踪 | 复宏汉霖 07月11日卖空量成交7500股，卖空比例为0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550939736","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550939736?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:30","pubTimestamp":1752222632,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间07月11日，跌5.68%，卖空量成交7500股%，较上一交易日减少62.87%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711172621a6a37e9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711172621a6a37e9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2550600162","title":"复宏汉霖盘中异动 下午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550600162","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550600162?lang=zh_cn&edition=full","pubTime":"2025-07-11 13:10","pubTimestamp":1752210630,"startTime":"0","endTime":"0","summary":"2025年07月11日下午盘13时10分，复宏汉霖股票出现波动，股价急速下挫5.05%。截至发稿，该股报52.650港元/股，成交量67.91万股，换手率0.42%，振幅5.77%。资金方面，该股资金流入665.287万港元，流出2851.2万港元。复宏汉霖股票所在的生物技术行业中，整体涨幅为2.39%。复宏汉霖公司简介：上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711131031a443f964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711131031a443f964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2550395436","title":"复宏汉霖(2696.HK)HLX43获多国批准开展NSCLC国际多中心II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2550395436","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550395436?lang=zh_cn&edition=full","pubTime":"2025-07-09 18:39","pubTimestamp":1752057574,"startTime":"0","endTime":"0","summary":"格隆汇7月9日｜近日，复宏汉霖创新型程序性死亡-配体1抗体偶联药物注射用HLX43全球开发再度取得重要进展，该产品已获得中国国家药品监督管理局、美国食品药品监督管理局、澳大利亚药品管理局及日本药品医疗器械综合机构许可，开展针对晚期非小细胞肺癌的国际多中心II期临床研究，并于此前在中国境内完成首例受试者给药。全球尚无同类靶向PD-L1的ADC产品获批上市，HLX43为全球首个进入临床II期的PD-L1 ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709184018953c09a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709184018953c09a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2550313156","title":"2025上半年BD王者榜：国产创新药的国际突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2550313156","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550313156?lang=zh_cn&edition=full","pubTime":"2025-07-09 17:45","pubTimestamp":1752054334,"startTime":"0","endTime":"0","summary":"二、技术出海先锋：和铂医药在2025年上半年的生物医药BD交易市场中，和铂医药同样表现得极为亮眼，成为了授权合作数量方面的佼佼者，凭借7项授权交易独占鳌头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709190104a69f4bdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709190104a69f4bdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1583","688336","02142","BK1574","688177","02696","BK1161","01530","BK1593"],"gpt_icon":0},{"id":"2550359346","title":"每日卖空追踪 | 复宏汉霖 07月09日卖空量成交6800股，卖空比例为0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550359346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550359346?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:30","pubTimestamp":1752049833,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间07月09日，涨1.91%，卖空量成交6800股%，较上一交易日减少75.45%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709172522a44005db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709172522a44005db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2550101680","title":"复宏汉霖07月09日主力净流入697.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550101680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550101680?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:15","pubTimestamp":1752048959,"startTime":"0","endTime":"0","summary":"07月09日, 复宏汉霖股价涨1.91%，报收55.90元，成交金额4950.2万元，换手率0.55%，振幅5.56%，量比0.80。复宏汉霖今日主力资金净流入697.8万元，上一交易日主力净流出434.9万元。该股近5个交易日上涨6.79%，主力资金累计净流入1468.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入6269.3万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170655a69f0db4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170655a69f0db4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2549512116","title":"复宏汉霖07月08日遭主力抛售434.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549512116","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549512116?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:15","pubTimestamp":1751962554,"startTime":"0","endTime":"0","summary":"07月08日, 复宏汉霖股价跌0.36%，报收54.85元，成交金额4343.5万元，换手率0.48%，振幅3.91%，量比0.53。复宏汉霖今日主力资金净流出434.9万元，上一交易日主力净流出465.1万元。该股近5个交易日上涨3.88%，主力资金累计净流入1371.5万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入6855.3万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170025a69ccb3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170025a69ccb3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2549533564","title":"每日卖空追踪 | 复宏汉霖 07月07日卖空量成交9200股，卖空比例为0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549533564","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549533564?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:30","pubTimestamp":1751877033,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间07月07日，跌1.52%，卖空量成交9200股%，较上一交易日减少35.21%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707172121a43b847e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707172121a43b847e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2548362764","title":"每日卖空追踪 | 复宏汉霖 07月04日卖空量成交2300股，卖空比例为0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548362764","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548362764?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:30","pubTimestamp":1751617833,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间07月04日，跌0.09%，卖空量成交2300股%，较上一交易日减少89.73%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704172336a4369ffc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704172336a4369ffc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2548733304","title":"从“减重效率”到“减重质量”，GLP-1“战争”下半场逻辑剧变","url":"https://stock-news.laohu8.com/highlight/detail?id=2548733304","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548733304?lang=zh_cn&edition=full","pubTime":"2025-07-04 07:36","pubTimestamp":1751585809,"startTime":"0","endTime":"0","summary":"司美格鲁肽与替尔泊肽均成为“药王级”产品，似乎GLP-1已然兑现了市场对它的期待。两大行业巨头礼来与诺和诺德，看似稳坐云端宝座，实则危机四伏，各路豪强对GLP-1下半场虎视眈眈。GLP-1争夺战并未结束，即将开启的下半场或将出现更大规模的拼杀。根据辉瑞预测，2030年GLP-1市场的规模将达到约900亿美元，口服产品预计到2030年将占据GLP-1市场约30%的份额，主要原因是患者对口服制剂的偏好较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704074156a72d7aa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704074156a72d7aa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","02696","02359","600276","06618","02269","01877","BK1583","03692","AMGN","NVO","01801","BK1100","02142","BK1589","06160","02096","BK1585","00853","06855","LLY"],"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0671},{"period":"1month","weight":0.2124},{"period":"3month","weight":0.757},{"period":"6month","weight":2.1362},{"period":"1year","weight":1.6452},{"period":"ytd","weight":1.5169}],"compareEarnings":[{"period":"1week","weight":0.0262},{"period":"1month","weight":0.019},{"period":"3month","weight":0.1459},{"period":"6month","weight":0.2519},{"period":"1year","weight":0.383},{"period":"ytd","weight":0.2222}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01（汉利康）、赫赛汀（曲妥珠单抗）生物类似药HLX02、修美乐（阿达木单抗）生物类似药HLX03和安维汀（贝伐珠单抗）生物类似药HLX04以及候选生物创新药，包括HLX06（一种新型VEGFR2抑制剂）、HLX07（一种EGFR抑制剂）、HLX10（一种新型PD-1抑制剂）、HLX20（一种新型PD-L1抑制剂）及HLX22（一种新型HER2抑制剂）等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052523},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.036789},{"month":8,"riseRate":0.4,"avgChangeRate":-0.051626},{"month":9,"riseRate":0,"avgChangeRate":-0.146246},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.017718},{"month":11,"riseRate":0.666667,"avgChangeRate":0.070363},{"month":12,"riseRate":0.833333,"avgChangeRate":0.001179}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}